However, oral formulations have changed that landscape
We've incorporated MCT oil, a wellspring of nourishing healthy fats
Since retatrutide does not hold MHRA or EMA marketing authorisation, no SmPC, PIL, or NICE guidance specific to this compound is available to the public
Key findings from the Phase 2 trial included: Dose-dependent reductions in body weight across all active treatment arms Significant improvements in waist circumference, a key marker of visceral adiposity Reductions in fasting insulin levels and HbA1c Improvements in lipid profiles, including triglycerides Phase 3 trials are currently ongoing and are expected to include larger, more diverse populations with more granular subgroup analyses, including sex-specific data
Gerti Tashko, MD, is an endocrinologist in Montgomery County, Maryland